ICER to Evaluate Value and Efficacy of Five COVID-19 Treatments
August 27, 2021
The Institute for Clinical and Economic Review (ICER) announced it will carry out assessments for five drugs used to treat COVID-19. Treatments include Regeneron’s casirivimab/imdevimab, Pfizer’s PF-07321332/ritonavir, and Merck’s molnupiravir.
“Consistent with ICER’s process for announcing new assessments, we have spent the past five weeks engaging with targeted stakeholders, including the manufacturers of the treatments being assessed, clinical specialists, as well as payers. Based on this preliminary cross-stakeholder engagement, today ICER has posted a Draft Scoping Document outlining how we plan to conduct this assessment.” Read more here.
(Source: ICER, 8/26/21)